Estriol (17b-triol) ELISA Kit Salivar

Os kits da Salimetrics são desenvolvidos e especificamente designados para a pesquisa com SALIVA, e trazem resultados precisos e acurados para os biomarcadores nela presentes.

Kit ideal para determinação quantitativa de Estriol (17b-triol) em amostras de saliva.

• Volume de amostra: 25 µL / 100 µL of X2 dilution (High sensitivity kit)
• Sensibilidade: 16 pg/mL / 1 pg/mL (High sensitivity kit)
• Tempo de ensaio: 24 horas
• Faixa de detecção: 20 - 4860 pg/mL /  5 - 1215 pg/mL (High sensitivity kit)
• Testes por unicata: 76
• Testes por duplicata: 38

Referências

Troisi, R., Potischman, N., Roberts, J.M., et al. (2003). Maternal serum oestrogen and androgen concentrations in preeclamptic and uncomplicated pregnancies.  Int J Epidemiol, 32(3), 455-60.

Reis, F.M., D’Antona, D., Petraglia, F. (2002).  Predictive value of hormone measurements in maternal and fetal complications of pregnancy. Endocr Rev, 23(2), 230-57.

Vining, R.F., McGinley, R., Rice, B.V. (1983). Saliva estriol measurements: An alternative to the assay of serum unconjugated estriol in assessing feto-placental function.  J Clin Endocrinol Metab, 56(3), 454-60.

Kirkish, L.S., Compton, A.A., McCann, D.S. (1986). Salivary estriol as an index to fetal wellbeing.  Clin Chem, 32(1 Pt 1), 71-75.

Heine, R.P., McGregor, J.A., Goodwin, T.M., et al. (2000). Serial salivary estriol to detect an increased risk of preterm birth. Obstet Gynecol, 96(4), 490-97.

Weintrob, N., Drouin, J., Vallette-Kasic, S., et al. (2005).  Low estriol levels in the maternal triple-marker screen as a predictor of isolated adrenocorticotropic hormone deficiency caused by a new mutation in the TPIT gene.  Pediatrics, 117(2), e322-7.

Canick, J.A., MacRae, A.R. (2005). Second trimester serum markers.  Semin Perinatol, 29(4), 203-8.

Watson, C.S., Jeng, Y.-J., Kochukov, M.Y. (2008).  Nongenomic actions of estradiol compared with estrone and estriol in pituitary tumor cell signaling and proliferation. FASEB J, 22(9), 3328-36.

Jacobson, H.I., Lemanski, N., Agarwal, A., et al. (2010). A proposed unified mechanism for the reduction of human breast cancer risk by the hormones of pregnancy.  Cancer Prev Res (Phil Pa), 3(2), 212-20.

Larfors, G., Lambert, P.C., Lambe, M., et al. (2009).  Placental weight and breast cancer survival in young women.  Cancer Epid Biomark Prev, 18(3), 777-83.

Hickey, M., Saunders, C., Partridge, A., et al. (2008). Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer.  Ann Oncol, 19(10), 1669-80.

Mascarenhas, C., Lambe, M., Bellocco, R., et al. (2006). Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival.  Int J Cancer, 119(12), 2907-15.

MacMahon, B. (2006).  Epidemiology and the causes of breast cancer.  Int J Cancer, 118(10), 2373-78.

Lagiou, P., Samoli, E., Lagiou, A., et al. (2005).  Maternal height, pregnancy estriol and birth weight in reference to breast cancer risk in Boston and Shanghai.  Int J Cancer, 117(3), 494-98.

Kassi, E., Moutsatsou, P. (2010). Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus.  J Biomed Biotech, 2010:317452.

Ding, J., Zhu, B.T. (2007). Unique effect of the pregnancy hormone estriol on antigen-induced production of specific antibodies in female BALB/c mice.  Steroids, 73(3), 289-98.

Rovenský, J. (2006).  Rheumatic diseases and Klinefelter’s syndrome: Review. Scripta Med (Brno), 79(4), 237-46.

Sicotte, N.L., Liva, S.M., Klutch, R., et al. (2002).  Treatment of multiple sclerosis with the pregnancy hormone estriol.  Ann Neurol, 52(4), 421-28.

Soldan, S.S., Alvarez-Retuerto, A.I., Sicotte, N.L., Voskuhl, R.R. (2003). Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol.  J Immunol, 171(11), 6267-74.

Kika, G., Izumi, S.-I., Mori, A., et al. (2009).  Beneficial aspect of oral estriol as hormone replacement therapy: Consideration on bone and lipid metabolism.  Tokai J Exp Clin Med, 34(3), 92-98.

Drača, S. (2006). Estriol and progesterone: A new role for sex hormones.  Int J Biomed Sci, 2(4), 305-7.

Moutsatsou, V., Oakey, R.E. (1988).  Oestriol binding to plasma proteins.  J Steroid Biochem, 29(3), 319-23.

Vining, R.F., McGinley, R.A., Symons, R.G. (1983).  Hormones in saliva: Mode of entry and consequent implications for clinical interpretation.  Clin Chem, 29(10), 1752-56.

Evans, J.J., Wilkinson, A.R., Aickin, D.R. (1984).  Salivary estriol concentrations during normal pregnancies, and a comparison with plasma estriol.  Clin Chem, 30(1), 120-21.